{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T14:36:21Z","timestamp":1767969381820,"version":"3.49.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,11,10]],"date-time":"2015-11-10T00:00:00Z","timestamp":1447113600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Australia New Zealand Breast Cancer Trials Group"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1007\/s00520-015-3001-5","type":"journal-article","created":{"date-parts":[[2015,11,9]],"date-time":"2015-11-09T23:08:46Z","timestamp":1447110526000},"page":"2139-2146","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Aromatase inhibitor induced musculoskeletal syndrome: a significant problem with limited treatment options"],"prefix":"10.1007","volume":"24","author":[{"given":"Janine M.","family":"Lombard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Zdenkowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathy","family":"Wells","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinna","family":"Beckmore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Reaby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John F.","family":"Forbes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacquie","family":"Chirgwin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,11,10]]},"reference":[{"issue":"5","key":"3001_CR1","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1200\/jco.2006.08.8617","volume":"25","author":"AS Coates","year":"2007","unstructured":"Coates AS, Keshaviah A, Th\u00fcrlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, L\u00e1ng I, Del Mastro L, Smith I, Chirgwin J, Nogaret J-M, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A (2007) Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25(5):486\u2013492. doi: 10.1200\/jco.2006.08.8617","journal-title":"J Clin Oncol"},{"issue":"9561","key":"3001_CR2","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S0140-6736(07)60200-1","volume":"369","author":"RC Coombes","year":"2007","unstructured":"Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, Van de Velde CJH, Delozier T, Alvarez I, Del Mastro L, Ortmann O, Diedrich K, Coates AS, Bajetta E, Holmberg SB, Dodwell D, Mickiewicz E, Andersen J, L\u00f8nning PE, Cocconi G, Forbes J, Castiglione M, Stuart N, Stewart A, Fallowfield LJ, Bertelli G, Hall E, Bogle RG, Carpentieri M, Colajori E, Subar M, Ireland E, Bliss JM (2007) Survival and safety of exemestane versus tamoxifen after 2\u20133\u00a0years\u2019 tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369(9561):559\u2013570","journal-title":"Lancet"},{"issue":"1","key":"3001_CR3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S1470-2045(07)70385-6","volume":"9","author":"The Arimidex TAoiCATG","year":"2008","unstructured":"The Arimidex TAoiCATG (2008) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9(1):45\u201353. doi: 10.1016\/S1470-2045(07)70385-6","journal-title":"Lancet Oncol"},{"issue":"8","key":"3001_CR4","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1093\/annonc\/mdq699","volume":"22","author":"A Lintermans","year":"2011","unstructured":"Lintermans A, Van Calster B, Van Hoydonck M, Pans S, Verhaeghe J, Westhovens R, Henry NL, Wildiers H, Paridaens R, Dieudonn\u00e9 AS, Leunen K, Morales L, Verschueren K, Timmerman D, De Smet L, Vergote I, Christiaens MR, Neven P (2011) Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis. Ann Oncol 22(8):1763\u20131769. doi: 10.1093\/annonc\/mdq699","journal-title":"Ann Oncol"},{"issue":"9922","key":"3001_CR5","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/s0140-6736(13)62292-8","volume":"383","author":"J Cuzick","year":"2014","unstructured":"Cuzick J, Sestak I, Forbes JF, Dowsett M, Knox J, Cawthorn S, Saunders C, Roche N, Mansel RE, von Minckwitz G, Bonanni B, Palva T, Howell A (2014) Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet 383(9922):1041\u20131048. doi: 10.1016\/s0140-6736(13)62292-8","journal-title":"Lancet"},{"issue":"1","key":"3001_CR6","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s10549-009-0692-7","volume":"120","author":"K Briot","year":"2010","unstructured":"Briot K, Tubiana-Hulin M, Bastit L, Kloos I, Roux C (2010) Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study. Breast Cancer Res Treat 120(1):127\u2013134. doi: 10.1007\/s10549-009-0692-7","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"3001_CR7","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1200\/jco.2011.38.0261","volume":"30","author":"NL Henry","year":"2012","unstructured":"Henry NL, Azzouz F, Desta Z, Li L, Nguyen AT, Lemler S, Hayden J, Tarpinian K, Yakim E, Flockhart DA, Stearns V, Hayes DF, Storniolo AM (2012) Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol 30(9):936\u2013942. doi: 10.1200\/jco.2011.38.0261","journal-title":"J Clin Oncol"},{"key":"3001_CR8","unstructured":"Porter D (2013) New Zealand survey of aromatase inhibitor toxicity"},{"issue":"10","key":"3001_CR9","doi-asserted-by":"publisher","first-page":"775","DOI":"10.3816\/CBC.2007.n.038","volume":"7","author":"CA Presant","year":"2007","unstructured":"Presant CA, Bosserman L, Young T, Vakil M, Horns R, Upadhyaya G, Ebrahimi B, Yeon C, Howard F (2007) Aromatase inhibitor\u2013associated arthralgia and\/or bone pain: frequency and characterization in non\u2013clinical trial patients. Clin Breast Cancer 7(10):775\u2013778. doi: 10.3816\/CBC.2007.n.038","journal-title":"Clin Breast Cancer"},{"key":"3001_CR10","volume-title":"Side effects revisitied: Women\u2019s experiences with aromatase inhibitors","author":"MT Zivian","year":"2008","unstructured":"Zivian MT, Salgado B (2008) Side effects revisitied: Women\u2019s experiences with aromatase inhibitors. Breast Cancer Action, San Francisco"},{"issue":"1","key":"3001_CR11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s10549-014-2986-7","volume":"146","author":"A Lintermans","year":"2014","unstructured":"Lintermans A, Van Asten K, Wildiers H, Laenen A, Paridaens R, Weltens C, Verhaeghe J, Vanderschueren D, Smeets A, Van Limbergen E, Leunen K, Christiaens MR, Neven P (2014) A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI. Breast Cancer Res Treat 146(1):109\u2013116. doi: 10.1007\/s10549-014-2986-7","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"3001_CR12","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1038\/bjc.2013.518","volume":"109","author":"TI Barron","year":"2013","unstructured":"Barron TI, Cahir C, Sharp L, Bennett K (2013) A nested case\u2013control study of adjuvant hormonal therapy persistence and compliance, and early breast cancer recurrence in women with stage I-III breast cancer. Br J Cancer 109(6):1513\u20131521. doi: 10.1038\/bjc.2013.518","journal-title":"Br J Cancer"},{"key":"3001_CR13","unstructured":"Chirgwin J, Giobbie-Hurder A. Treatment adherence in the BIG 1-98 trial of tamoxifen, letrozole alone and in sequence"},{"issue":"2","key":"3001_CR14","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s10549-010-1132-4","volume":"126","author":"DL Hershman","year":"2011","unstructured":"Hershman DL, Shao T, Kushi LH, Buono D, Tsai WY, Fehrenbacher L, Kwan M, Gomez SL, Neugut AI (2011) Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 126(2):529\u2013537. doi: 10.1007\/s10549-010-1132-4","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"3001_CR15","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1038\/bjc.2013.116","volume":"108","author":"B Makubate","year":"2013","unstructured":"Makubate B, Donnan PT, Dewar JA, Thompson AM, McCowan C (2013) Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. Br J Cancer 108(7):1515\u20131524. doi: 10.1038\/bjc.2013.116","journal-title":"Br J Cancer"},{"issue":"11","key":"3001_CR16","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1038\/sj.bjc.6604758","volume":"99","author":"C McCowan","year":"2008","unstructured":"McCowan C, Shearer J, Donnan PT, Dewar JA, Crilly M, Thompson AM, Fahey TP (2008) Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer 99(11):1763\u20131768. doi: 10.1038\/sj.bjc.6604758","journal-title":"Br J Cancer"},{"issue":"5","key":"3001_CR17","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1038\/bjc.2013.464","volume":"109","author":"C McCowan","year":"2013","unstructured":"McCowan C, Wang S, Thompson AM, Makubate B, Petrie DJ (2013) The value of high adherence to tamoxifen in women with breast cancer: a community-based cohort study. Br J Cancer 109(5):1172\u20131180. doi: 10.1038\/bjc.2013.464","journal-title":"Br J Cancer"},{"issue":"3","key":"3001_CR18","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1200\/jco.2014.57.6926","volume":"33","author":"V Stearns","year":"2015","unstructured":"Stearns V, Chapman JA, Ma CX, Ellis MJ, Ingle JN, Pritchard KI, Budd GT, Rabaglio M, Sledge GW, Le Maitre A, Kundapur J, Liedke PE, Shepherd LE, Goss PE (2015) Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial. J Clin Oncol 33(3):265\u2013271. doi: 10.1200\/jco.2014.57.6926","journal-title":"J Clin Oncol"},{"issue":"4","key":"3001_CR19","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/s1470-2045(11)70328-x","volume":"13","author":"JS Mieog","year":"2012","unstructured":"Mieog JS, Morden JP, Bliss JM, Coombes RC, van de Velde CJ (2012) Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2\u20133\u00a0years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study. Lancet Oncol 13(4):420\u2013432. doi: 10.1016\/s1470-2045(11)70328-x","journal-title":"Lancet Oncol"},{"issue":"12","key":"3001_CR20","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/s1470-2045(08)70259-6","volume":"9","author":"J Cuzick","year":"2008","unstructured":"Cuzick J, Sestak I, Cella D, Fallowfield L (2008) Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol 9(12):1143\u20131148. doi: 10.1016\/s1470-2045(08)70259-6","journal-title":"Lancet Oncol"},{"issue":"18","key":"3001_CR21","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1200\/jco.2012.45.3068","volume":"31","author":"DB Fontein","year":"2013","unstructured":"Fontein DB, Seynaeve C, Hadji P, Hille ET, van de Water W, Putter H, Kranenbarg EM, Hasenburg A, Paridaens RJ, Vannetzel JM, Markopoulos C, Hozumi Y, Bartlett JM, Jones SE, Rea DW, Nortier JW, van de Velde CJ (2013) Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: an international tamoxifen exemestane adjuvant multinational trial analysis. J Clin Oncol 31(18):2257\u20132264. doi: 10.1200\/jco.2012.45.3068","journal-title":"J Clin Oncol"},{"issue":"1","key":"3001_CR22","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s10549-013-2792-7","volume":"143","author":"J Huober","year":"2014","unstructured":"Huober J, Cole BF, Rabaglio M, Giobbie-Hurder A, Wu J, Ejlertsen B, Bonnefoi H, Forbes JF, Neven P, Lang I, Smith I, Wardley A, Price KN, Goldhirsch A, Coates AS, Colleoni M, Gelber RD, Thurlimann B (2014) Symptoms of endocrine treatment and outcome in the BIG 1-98 study. Breast Cancer Res Treat 143(1):159\u2013169. doi: 10.1007\/s10549-013-2792-7","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"3001_CR23","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1200\/jco.2009.23.4708","volume":"28","author":"KD Crew","year":"2010","unstructured":"Crew KD, Capodice JL, Greenlee H, Brafman L, Fuentes D, Awad D, Yann Tsai W, Hershman DL (2010) Randomized, blinded, sham-controlled trial of acupuncture for the management of aromatase inhibitor\u2013associated joint symptoms in women with early-stage breast cancer. J Clin Oncol 28(7):1154\u20131160. doi: 10.1200\/jco.2009.23.4708","journal-title":"J Clin Oncol"},{"issue":"2","key":"3001_CR24","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.ejca.2013.09.022","volume":"50","author":"JJ Mao","year":"2014","unstructured":"Mao JJ, Xie SX, Farrar JT, Stricker CT, Bowman MA, Bruner D, DeMichele A (2014) A randomised trial of electro-acupuncture for arthralgia related to aromatase inhibitor use. Eur J Cancer 50(2):267\u2013276. doi: 10.1016\/j.ejca.2013.09.022","journal-title":"Eur J Cancer"},{"issue":"10","key":"3001_CR25","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1200\/jco.2014.57.1547","volume":"33","author":"ML Irwin","year":"2015","unstructured":"Irwin ML, Cartmel B, Gross CP, Ercolano E, Li F, Yao X, Fiellin M, Capozza S, Rothbard M, Zhou Y, Harrigan M, Sanft T, Schmitz K, Neogi T, Hershman D, Ligibel J (2015) Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors. J Clin Oncol 33(10):1104\u20131114. doi: 10.1200\/jco.2014.57.1547","journal-title":"J Clin Oncol"},{"key":"3001_CR26","doi-asserted-by":"crossref","unstructured":"Rastelli AL, Taylor ME, Villareal R, Jamalabadi-Majidi S, Gao F, Ellis MJ (2009) A double blind randomised placebo controlled trial of high dose vitamin D therapy on musculoskeletal pain and bone mineral density in anastrazole treated breast cancer patients with marginal vitamin D status. Paper presented at the San Antonio Breast Cancer Symposium, San Antonio","DOI":"10.1158\/0008-5472.SABCS-09-803"},{"issue":"4","key":"3001_CR27","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1007\/s00520-012-1628-z","volume":"21","author":"H Greenlee","year":"2013","unstructured":"Greenlee H, Crew K, Shao T, Kranwinkel G, Kalinsky K, Maurer M, Brafman L, Insel B, Tsai W, Hershman D (2013) Phase II study of glucosamine with chondroitin on aromatase inhibitor-associated joint symptoms in women with breast cancer. Support Care Cancer 21(4):1077\u20131087. doi: 10.1007\/s00520-012-1628-z","journal-title":"Support Care Cancer"},{"issue":"6","key":"3001_CR28","first-page":"2331","volume":"32","author":"M Kubo","year":"2012","unstructured":"Kubo M, Onishi H, Kuroki S, Okido M, Shimada K, Yokohata K, Umeda S, Ogawa T, Tanaka M, Katano M (2012) Short-term and low-dose prednisolone administration reduces aromatase inhibitor-induced arthralgia in patients with breast cancer. Anticancer Res 32(6):2331\u20132336","journal-title":"Anticancer Res"},{"issue":"24","key":"3001_CR29","doi-asserted-by":"publisher","first-page":"5469","DOI":"10.1002\/cncr.26230","volume":"117","author":"NL Henry","year":"2011","unstructured":"Henry NL, Banerjee M, Wicha M, Van Poznak C, Smerage JB, Schott AF, Griggs JJ, Hayes DF (2011) Pilot study of duloxetine for treatment of aromatase inhibitor-associated musculoskeletal symptoms. Cancer 117(24):5469\u20135475. doi: 10.1002\/cncr.26230","journal-title":"Cancer"},{"key":"3001_CR30","volume-title":"Cancer in Australia: an overview, 2014. vol Cancer series no. 90","author":"AIHW","year":"2014","unstructured":"AIHW (2014) Cancer in Australia: an overview, 2014. vol Cancer series no. 90. Australian Institute of Health and Welfare & Australasian Association of Cancer Registries, Canberra"},{"key":"3001_CR31","unstructured":"Division PB (2011) Australian Statistics on Medicines. Commonwealth of Australia. http:\/\/www.pbs.gov.au\/info\/statistics\/asm\/asm-2011 . Accessed 7 Jan 2015"},{"issue":"4","key":"3001_CR32","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.breast.2008.02.006","volume":"17","author":"C Fontaine","year":"2008","unstructured":"Fontaine C, Meulemans A, Huizing M, Collen C, Kaufman L, De Mey J, Bourgain C, Verfaillie G, Lamote J, Sacre R, Schallier D, Neyns B, Vermorken J, De Gr\u00e8ve J (2008) Tolerance of adjuvant letrozole outside of clinical trials. Breast (Edinburgh, Scotland) 17(4):376\u2013381","journal-title":"Breast (Edinburgh, Scotland)"},{"issue":"2","key":"3001_CR33","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s10549-007-9774-6","volume":"111","author":"N Henry","year":"2008","unstructured":"Henry N, Giles J, Ang D, Mohan M, Dadabhoy D, Robarge J, Hayden J, Lemler S, Shahverdi K, Powers P, Li L, Flockhart D, Stearns V, Hayes D, Storniolo AM, Clauw D (2008) Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat 111(2):365\u2013372. doi: 10.1007\/s10549-007-9774-6","journal-title":"Breast Cancer Res Treat"},{"issue":"16","key":"3001_CR34","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1002\/cncr.28756","volume":"120","author":"KM Kidwell","year":"2014","unstructured":"Kidwell KM, Harte SE, Hayes DF, Storniolo AM, Carpenter J, Flockhart DA, Stearns V, Clauw DJ, Williams DA, Henry NL (2014) Patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy. Cancer 120(16):2403\u20132411. doi: 10.1002\/cncr.28756","journal-title":"Cancer"},{"issue":"9","key":"3001_CR35","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/s1470-2045(08)70182-7","volume":"9","author":"I Sestak","year":"2008","unstructured":"Sestak I, Cuzick J, Sapunar F, Eastell R, Forbes JF, Bianco AR, Buzdar AU (2008) Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol 9(9):866\u2013872. doi: 10.1016\/s1470-2045(08)70182-7","journal-title":"Lancet Oncol"},{"issue":"25","key":"3001_CR36","doi-asserted-by":"publisher","first-page":"3877","DOI":"10.1200\/jco.2007.10.7573","volume":"25","author":"KD Crew","year":"2007","unstructured":"Crew KD, Greenlee H, Capodice J, Raptis G, Brafman L, Fuentes D, Sierra A, Hershman DL (2007) Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 25(25):3877\u20133883. doi: 10.1200\/jco.2007.10.7573","journal-title":"J Clin Oncol"},{"issue":"1","key":"3001_CR37","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1345\/aph.1R369","volume":"47","author":"MG Hashem","year":"2013","unstructured":"Hashem MG, Cleary K, Fishman D, Nichols L, Khalid M (2013) Effect of concurrent prescription antiarthralgia pharmacotherapy on persistence to aromatase inhibitors in treatment-naive postmenopausal females. Ann Pharmacother 47(1):29\u201334. doi: 10.1345\/aph.1R369","journal-title":"Ann Pharmacother"},{"issue":"1","key":"3001_CR38","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.maturitas.2010.04.009","volume":"67","author":"M Magliano","year":"2010","unstructured":"Magliano M (2010) Menopausal arthralgia: fact or fiction. Maturitas 67(1):29\u201333. doi: 10.1016\/j.maturitas.2010.04.009","journal-title":"Maturitas"},{"issue":"9","key":"3001_CR39","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/s1470-2045(08)70217-1","volume":"9","author":"AL Tan","year":"2008","unstructured":"Tan AL, Emery P (2008) Role of oestrogen in the development of joint symptoms? Lancet Oncol 9(9):817\u2013818. doi: 10.1016\/s1470-2045(08)70217-1","journal-title":"Lancet Oncol"},{"issue":"4","key":"3001_CR40","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/s1297-319x(03)00067-8","volume":"70","author":"P Richette","year":"2003","unstructured":"Richette P, Corvol M, Bardin T (2003) Estrogens, cartilage, and osteoarthritis. Joint Bone Spine 70(4):257\u2013262. doi: 10.1016\/s1297-319x(03)00067-8","journal-title":"Joint Bone Spine"},{"issue":"9","key":"3001_CR41","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1002\/art.21364","volume":"52","author":"DT Felson","year":"2005","unstructured":"Felson DT, Cummings SR (2005) Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation. Arthritis Rheumatism 52(9):2594\u20132598. doi: 10.1002\/art.21364","journal-title":"Arthritis Rheumatism"},{"issue":"3","key":"3001_CR42","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/sj.bjc.6605768","volume":"103","author":"NL Henry","year":"2010","unstructured":"Henry NL, Pchejetski D, A\u2019Hern R, Nguyen AT, Charles P, Waxman J, Li L, Storniolo AM, Hayes DF, Flockhart DA, Stearns V, Stebbing J (2010) Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case\u2013control study. Br J Cancer 103(3):291\u2013296. doi: 10.1038\/sj.bjc.6605768","journal-title":"Br J Cancer"},{"issue":"17","key":"3001_CR43","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1016\/j.ejca.2014.08.012","volume":"50","author":"A Lintermans","year":"2014","unstructured":"Lintermans A, Vanderschueren D, Verhaeghe J, Van Asten K, Jans I, Van Herck E, Laenen A, Paridaens R, Billen J, Pauwels S, Vermeersch P, Wildiers H, Christiaens MR, Neven P (2014) Arthralgia induced by endocrine treatment for breast cancer: a prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogens. Eur J Cancer 50(17):2925\u20132931. doi: 10.1016\/j.ejca.2014.08.012","journal-title":"Eur J Cancer"},{"issue":"1","key":"3001_CR44","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s10549-011-1644-6","volume":"129","author":"AL Rastelli","year":"2011","unstructured":"Rastelli AL, Taylor ME, Gao F, Armamento-Villareal R, Jamalabadi-Majidi S, Napoli N, Ellis MJ (2011) Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial. Breast Cancer Res Treat 129(1):107\u2013116. doi: 10.1007\/s10549-011-1644-6","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"3001_CR45","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s10549-009-0495-x","volume":"119","author":"QJ Khan","year":"2010","unstructured":"Khan QJ, Reddy PS, Kimler BF, Sharma P, Baxa SE, O\u2019Dea AP, Klemp JR, Fabian CJ (2010) Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Res Treat 119(1):111\u2013118. doi: 10.1007\/s10549-009-0495-x","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"3001_CR46","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s10549-010-1075-9","volume":"125","author":"D Prieto-Alhambra","year":"2011","unstructured":"Prieto-Alhambra D, Javaid MK, Servitja S, Arden NK, Martinez-Garcia M, Diez-Perez A, Albanell J, Tusquets I, Nogues X (2011) Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study. Breast Cancer Res Treat 125(3):869\u2013878. doi: 10.1007\/s10549-010-1075-9","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"3001_CR47","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s10549-013-2638-3","volume":"140","author":"N Garcia-Giralt","year":"2013","unstructured":"Garcia-Giralt N, Rodriguez-Sanz M, Prieto-Alhambra D, Servitja S, Torres-Del Pliego E, Balcells S, Albanell J, Grinberg D, Diez-Perez A, Tusquets I, Nogues X (2013) Genetic determinants of aromatase inhibitor-related arthralgia: the B-ABLE cohort study. Breast Cancer Res Treat 140(2):385\u2013395. doi: 10.1007\/s10549-013-2638-3","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"3001_CR48","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1177\/1534735411413270","volume":"11","author":"ML Galantino","year":"2012","unstructured":"Galantino ML, Desai K, Greene L, Demichele A, Stricker CT, Mao JJ (2012) Impact of yoga on functional outcomes in breast cancer survivors with aromatase inhibitor-associated arthralgias. Integr Cancer Ther 11(4):313\u2013320. doi: 10.1177\/1534735411413270","journal-title":"Integr Cancer Ther"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-015-3001-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-015-3001-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-015-3001-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-015-3001-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T07:11:04Z","timestamp":1567321864000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-015-3001-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,10]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["3001"],"URL":"https:\/\/doi.org\/10.1007\/s00520-015-3001-5","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,10]]}}}